In the study of Forty-nine patients were randomized to receive either placebo, or a daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh, with each component standardized to its primary alkaloid. Patients received study medication for 24 weeks of "Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine" by Burke BE, Olson RD, Cusack BJ, posted in US National Library of Medicine National Institutes of Health, found that patients received study medication for 24 weeks. Average frequency of menstrually associated migraine attacks during weeks 9-24 was reduced from 10.3 +/- 2.4 (mean +/- s.e.m.) in placebo treated patients to 4.7 +/- 1.8 (P < 0.01) in patients treated with the phytoestrogen preparation.
Google Ads
Natural Medicine for Fatty Liver And Obesity Reversal
Thursday, February 16, 2012
Soy and Menstrual Migraine
Posted by Chantel M. Contributed by US National Library of Medicine National Institutes of Health
In the study of Forty-nine patients were randomized to receive either placebo, or a daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh, with each component standardized to its primary alkaloid. Patients received study medication for 24 weeks of "Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine" by Burke BE, Olson RD, Cusack BJ, posted in US National Library of Medicine National Institutes of Health, found that patients received study medication for 24 weeks. Average frequency of menstrually associated migraine attacks during weeks 9-24 was reduced from 10.3 +/- 2.4 (mean +/- s.e.m.) in placebo treated patients to 4.7 +/- 1.8 (P < 0.01) in patients treated with the phytoestrogen preparation.
In the study of Forty-nine patients were randomized to receive either placebo, or a daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh, with each component standardized to its primary alkaloid. Patients received study medication for 24 weeks of "Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine" by Burke BE, Olson RD, Cusack BJ, posted in US National Library of Medicine National Institutes of Health, found that patients received study medication for 24 weeks. Average frequency of menstrually associated migraine attacks during weeks 9-24 was reduced from 10.3 +/- 2.4 (mean +/- s.e.m.) in placebo treated patients to 4.7 +/- 1.8 (P < 0.01) in patients treated with the phytoestrogen preparation.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment